AXLRx Book a callCommission

Big Pharma · Company profile

Sanofi

Commission a Sanofi report

By therapy area

Therapy area All areas ImmunologyRare DiseasePulmonology

AXLRx reports featuring Sanofi

CI · Immunology · CI Team · Launch Lead US Atopic Dermatitis Competitive Intelligence Dupilumab's 70% biologic share against JAK step-edits. A two-tier US payer landscape for IL-4Ra biologics and oral JAKs. US · In-Market · Read report → CI · Rare Disease · CI Team · Launch Lead · Market Access US Gaucher Disease Competitive Intelligence Five FDA-approved Gaucher type 1 therapies (three IV enzyme replacement vs two oral substrate reduction) and eliglustat's oral first-line pivot. US · In-Market · Read report → CI · Rare Disease · CI Team · Launch Lead · Market Access US Pompe Disease Competitive Intelligence Two next-generation ERTs are moving to displace alglucosidase alfa in US late-onset Pompe disease. Avalglucosidase alfa and cipaglucosidase alfa plus miglustat now define the competitive set. US · In-Market · Read report → CI · Rare Disease · CI Team · Launch Lead · Market Access US Fabry Disease Competitive Intelligence Pegunigalsidase now challenges Fabrazyme's two-decade lead in US Fabry disease. Two IV enzyme replacement therapies meet an oral chaperone only ~35–50% of patients can take. US · In-Market · Read report → DL · Immunology · CI Team · Launch Lead US Atopic Dermatitis Disease Landscape US atopic dermatitis epidemiology — 16.5M adults, the moderate-to-severe pool, and the atopic march that frames the biologic-eligible segment. US · In-Market · Read report → CI · Pulmonology · CI Team · Launch Lead US COPD Competitive Intelligence Two 2024 approvals moved the COPD maintenance fight past the inhaler for the first time in a decade. Ensifentrine and dupilumab split the market into an inhaler base and a biology-defined add-on tier. US · In-Market · Read report →